Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women

Menopause

Volumn 10, Issue 6, 2003, Pages 544-549

  Jung, Gu Kim ^a   Young, Min Choi ^b   Shin, Yong Moon ^b   Jin, Yong Lee ^b  

^a Seoul National University Hospital   (South Korea)

^b NONE

Author keywords

Bone mineral density; Calcitonin; HT; Polymorphism

Indexed keywords

CALCITONIN; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ADULT; ALLELE; ARTICLE; BONE DENSITY; BONE MASS; CALCITONIN BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FEMUR; FEMUR NECK; HORMONAL THERAPY; HUMAN; KOREA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; BLOOD; DINUCLEOTIDE REPEAT; DRUG EFFECT; ESTROGEN THERAPY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; LUMBAR VERTEBRA; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS;

BONE DENSITY; CALCITONIN; COLLAGEN; COLLAGEN TYPE I; DINUCLEOTIDE REPEATS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FEMUR; FEMUR NECK; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; LUMBAR VERTEBRAE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; POLYMORPHISM, GENETIC;

EID: 2342477933     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000070525.74726.51     Document Type: Article

References (21)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17:1-45.
2. Jouanny P, Guillemin F, Kuntz C, Jaendel C, Pourel J. Environmental and genetic factors affecting bone mass. Similarity of bone density among members of healthy families. Arthritis Rheum 1995;38:61-67.
3. Zmuda JM, Cauley JA, Ferrell RE. Recent progress in understanding the genetic susceptibility to osteoporosis. Genet Epidemiol 1999;16:356-367.
4. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol 2000;166:235-245.
5. Kim JG, Lim KS, Kim EK, Choi YM, Lee JY. Association of vitamin D receptor and estrogen receptor gene polymorphisms with bone mass in postmenopausal Korean women. Menopause 2001;8:222-228.
6. Kim JG, Roh KR, Lee JY. The relationship among serum insulin-like growth factor-I, insulin-like growth factor-I gene polymorphism and bone mineral density in postmenopausal women in Korea. Am J Obstet Gynecol 2002;186:345-350.
7. Hoff AO, Cote GJ, Gagel RF. Calcitonin. In: Marcus R, Feldman D, Kelsey J eds. Osteoporosis. San Diego, CA: Academic Press; 2001:247-255.
8. Alevizaki M, Stevenson JC, Girgis SI, MacIntyre I, Legon S. Altered calcitonin gene in a young patient with osteoporosis. BMJ 1989;298:1215-1216.
9. Tsukamoto K, Emi M. A polymorphic CA repeat sequence at the human calcitonin locus. J Hum Genet 1998;43:146-147.
10. Miyao M, Hosoi T, Emi M, et al. Association of bone mineral density with a dinucleotide repeat polymorphism at the calcitonin (CT) locus. J Hum Genet 2000;45:346-350.
11. Silke CM, Wynne F, Quanne K, et al. Investigation of the association of dinucleotide repeats within the calcitonin and interleukin 6 receptor genes with low bone mineral density in the Irish poulation. J Bone Miner Res 2002;17(Suppl 1):S423.
12. Christgau S, Bitsch-Jensen O, Bjarnason NH, et al. Serum Cross-Laps for monitoring the response in individuals undergoing antiresortive therapy. Bone 2000;626:505-511.
13. Prince RL, Dick IM, Price RI. Plasma calcitonin levels are not lower than normal in osteoporotic women. J Clin Endocrinol Metab 1989;68:684-687.
14. Hassager C, Jensen SB, Christiansen C. Non-responders to hormone replacement herapy for the prevention of postmenopausal bone loss: Do they exist? Osteoporos Int 1994;4:36-41.
15. Komulainen M, Kroger H, Tuppurainen MT, Heikkinen AM, Honkanen R, Saarioski S. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporos Int 2000;11:211-218.
16. Deng HW, Li J, Li JL, et al. Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum Genet 1998;103:576-585.
17. Salmen T, Heikkinen AM, Mahonen A, et al. Early postmenopausal bone loss is associated with PvuI1 estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Ress 2000;15:315-321.
18. Han KO, Moon IG, Kang YS, Chung HY, Min HK, Han IK. Non-association of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J Clin Endocrinol Metab 1997;82:991-995.
19. Leggate J, Farish E, Fletcher CD, McIntosh W, Hart DM, Sommerville Calcitonin and postmenopausal osteoporosis. Clin Endocrinol 1984;20:85-92.
20. Stevenson JC, Abeyasekera G, Hillyard CJ, et al. Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens. Lancet 1981;1:693-695.
21. Hurley DL, Tiegs RD, Barta J, Laakso K, Heath H 3rd. Effects of oral contraceptive and estrogen administration on plasma calcitonin in pre- and postmenopausal women. J Bone Miner Res 1989;4:89-95.